Insulin lispro

Insulin — ALIMENTARY TRACT AND METABOLISM

Key facts

Insulin lispro is a drug in the Insulin class catalogued in DrugCentral. It was first approved by the EMA in 1996. DrugCentral lists 1 molecular target, including INSR. Recorded indications include Diabetes mellitus type 1 and Diabetes mellitus type 2.

• Drug class: Insulin; Insulin Analog.
• Molecular targets: INSR (1 listed in DrugCentral).
• Indications: Diabetes mellitus type 1 and Diabetes mellitus type 2.
• ATC code: A10AB04 (Insulins and analogues for injection, fast-acting).
• Molecular formula: C257H383N65O77S6; molecular weight 5807.63 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (2)

• Diabetes mellitus type 1
• Diabetes mellitus type 2

Mechanism & targets

• Established pharmacologic class: Insulin; Insulin Analog

Molecular targets (1)

Target	Gene	Action	Activity
Insulin receptor	INSR	agonist	—

Regulatory approvals (3)

Date	Agency	Marketed as	Applicant	Orphan
2020-03-25	PMDA	—	Eli Lilly Japan K.K.
1996-06-14	FDA	—	LILLY
1996-04-30	EMA	—	Eli Lilly Nederland B.V.

ATC classification

ATC code	Therapeutic hierarchy
A10AB04	ALIMENTARY TRACT AND METABOLISM › DRUGS USED IN DIABETES › INSULINS AND ANALOGUES › Insulins and analogues for injection, fast-acting
A10AC04	ALIMENTARY TRACT AND METABOLISM › DRUGS USED IN DIABETES › INSULINS AND ANALOGUES › Insulins and analogues for injection, intermediate-acting
A10AD04	ALIMENTARY TRACT AND METABOLISM › DRUGS USED IN DIABETES › INSULINS AND ANALOGUES › Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Blood glucose increased	5592.4
Hypoglycaemia	3210.5
Blood glucose decreased	1267.6
Diabetic ketoacidosis	1179.7
Diabetes mellitus inadequate control	1027.3
Hyperglycaemia	948.2
Product storage error	902.4
Blood glucose abnormal	814.1
Glycosylated haemoglobin increased	767.8
No adverse event	606.5
Incorrect dose administered	584.4
Blood glucose fluctuation	505.2

Chemical structure

• Molecular formula: C₂₅₇H₃₈₃N₆₅O₇₇S₆
• Molecular weight: 5807.63 g/mol
• CAS number: 133107-64-9
• InChIKey: —
• PubChem CID: 118984375

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Insulin lispro used for?

DrugCentral lists the following indications for Insulin lispro: Diabetes mellitus type 1 and Diabetes mellitus type 2.

How does Insulin lispro work?

Its molecular targets in DrugCentral include INSR (agonist).

When was Insulin lispro first approved?

Insulin lispro was first approved by the EMA in 1996.

What drug class does Insulin lispro belong to?

Insulin lispro is in the Insulin class.

What is the chemical formula of Insulin lispro?

Insulin lispro has the molecular formula C257H383N65O77S6 and a molecular weight of 5807.63 g/mol.

Sources

• DrugCentral drug card 5002 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1201538 — compound record and bioactivity
• PubChem CID 118984375 — chemical identifiers
• DrugBank DB00030 — drug record
• FDA UNII GFX7QIS1II — substance identity
• DailyMed: FDA labels for Insulin lispro — current prescribing information (label search)
• UniProt P06213 (INSR) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.